Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study.

doi:10.1186/s12879-017-2517-3

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study.

BMC infectious diseases - 13 Jun 2017

Cunningham Evan B, Hajarizadeh Behzad, Dalgard Olav, Amin Janaki, Hellard Margaret, Foster Graham R, Bruggmann Philip, Conway Brian, Backmund Markus, Robaeys Geert, Swan Tracy, Marks Philippa S, Quiene Sophie, Applegate Tanya L, Weltman Martin, Shaw David, Dunlop Adrian, Bruneau Julie, Midgard Håvard, Bourgeois Stefan, Thurnheer Maria Christine, Dore Gregory J, Grebely Jason

Abstract excerpt

BACKGROUND: The aims of this analysis were to investigate treatment completion and adherence among people with ongoing injecting drug use or receiving opioid substitution therapy (OST) in a study of response-guided therapy for chronic HCV genotypes 2/3 infection. METHODS: ACTIVATE was a multicenter clinical trial recruited between 2012 and 2014. Participants with genotypes 2/3 were treated with directly observed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis C

Share to Interferon-alpha

Share to Interferon alpha-2

Share to Patient Compliance

Share to Polyethylene Glycols

Share to Ribavirin

Share to Self Administration

Source

Open in PubMed Open full text

Identifiers

PMID: 28610605
DOI: 10.1186/s12879-017-2517-3
PMCID: PMC5470219

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study.PMID 28610605Read ↗

Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study.Semantic proximity Read ↗

Relationship between adherence to hepatitis C virus therapy and virologic outcomes: a cohort study.Semantic proximity Read ↗

Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.Semantic proximity Read ↗

Uptake of and Factors Associated With Direct-acting Antiviral Therapy Among Patients in the Chronic Hepatitis Cohort Study, 2014 to 2015.Semantic proximity Read ↗

Perspectives on Adherence From the ACTG 5360 MINMON Trial: A Minimum Monitoring Approach With 12 Weeks of Sofosbuvir/Velpatasvir in Chronic Hepatitis C Treatment.Semantic proximity Read ↗

Efficacy of peginterferon plus ribavirin in patients receiving opioid substitution therapy : Final results of the Austrian PegHope study.Semantic proximity Read ↗

Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials.Semantic proximity Read ↗

Interferon alpha therapy for hepatitis C: treatment completion and response rates among patients with substance use disorders.Semantic proximity Read ↗

Treatment adherence and virological response rates in hepatitis C virus infected persons treated with sofosbuvir-based regimens: results from ERCHIVES.Semantic proximity Read ↗

High efficacy of glecaprevir/pibrentasvir for HCV-infected individuals with active drug use.Semantic proximity Read ↗

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.Semantic proximity Read ↗

Response-guided therapy for hepatitis C genotype 2 and 3 in those with HIV coinfection.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.